Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

NCT ID: NCT05077280 Phase: PHASE2 Sponsor: California Pacific Medical Center Research Institute Status: Unknown

SUMMARY

This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years

KEY ELIGIBILITY CRITERIA

- * measurable metastatic uveal melanoma.
- * No concomitant therapy.
- * Prior PD1 or tebendafesp allowed.
- * Performance status 0-1.
- * No active Hepatitis B.
- * No known HIV infection.
- * WBC\>2000, ANC\>1500, Hgb \>8.
- * Creatinine \< 3 x ULN.
- * AST \& ALT \< 2.5 x ULN Bilirubin \< 2 x ULN.
- * Albumin \>2.9

ENROLLMENT CONTACT

Madeline Decker
California Pacific Medical Center Research Institute
San Francisco, California, United States
Phone: 415-600-3613
Email: KimB@sutterhealth.org

Total sites: 1 | 1 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05077280) and public sources. Generated by FindMyCure.ai.